Home โบ Ewing Sarcoma
Ewing Sarcoma clinical trials recruiting in the U.S.
33 studies for Ewing Sarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY8 studies
- Houston, TX7 studies
- Philadelphia, PA7 studies
- Memphis, TN7 studies
- Boston, MA6 studies
- Aurora, CO6 studies
- Los Angeles, CA6 studies
- Washington, DC6 studies
- Birmingham, AL5 studies
- Atlanta, GA5 studies
- Cincinnati, OH4 studies
- Phoenix, AZ4 studies
- Columbus, OH4 studies
- Salt Lake City, UT4 studies
- Tampa, FL4 studies
- Gainesville, FL4 studies
- Nashville, TN4 studies
- St. Petersburg, FL4 studies
- Grand Rapids, MI4 studies
- Baltimore, MD4 studies
- Orange, CA3 studies
- St. Louis, MO3 studies
- Dallas, TX3 studies
- Harrisburg, PA3 studies
- Hartford, CT3 studies
- Miami, FL3 studies
- Greenburgh, NY3 studies
- Minneapolis, MN3 studies
- San Francisco, CA3 studies
- Ann Arbor, MI3 studies
- The Bronx, NY3 studies
By state
- Alabama5 studies
- Arizona4 studies
- California12 studies
- Colorado6 studies
- Connecticut4 studies
- District of Columbia6 studies
- Florida7 studies
- Georgia5 studies
- Maryland4 studies
- Massachusetts6 studies
- Michigan8 studies
- Minnesota5 studies
- Missouri4 studies
- New Jersey4 studies
- New York12 studies
- Ohio8 studies
- Pennsylvania10 studies
- Tennessee11 studies
- Texas9 studies
- Utah4 studies
Recently updated studies
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
RecruitingPhase 1
Ages 1 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07194044Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
RecruitingPhase 1
Ages 2 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07297979Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months โ 25 Years ยท All sexes ยท Updated Sep 17, 2026 ยท NCT06395103Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
RecruitingPhase 1
Ages 12 to 85 ยท All sexes ยท Updated Sep 8, 2026 ยท NCT03715933Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06541262Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
Up to age 26 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06465199Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RecruitingPhase 1
Ages 5 to 40 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06156410Lurbinectedin in FET-Fused Tumors
RecruitingPhase 1/2
Ages 10 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
12 Months โ 30 Years ยท All sexes ยท Updated Aug 25, 2026 ยท NCT04851119Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Recruiting
All ages ยท All sexes ยท Updated Aug 21, 2026 ยท NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RecruitingPhase 1
Ages 1 to 23 ยท All sexes ยท Updated Aug 13, 2026 ยท NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 6, 2026 ยท NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Jul 31, 2026 ยท NCT07628634Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Recruiting
Up to age 39 ยท All sexes ยท Updated Jul 13, 2026 ยท NCT06796543Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
RecruitingPhase 2
Ages 0 to 50 ยท All sexes ยท Updated Jul 9, 2026 ยท NCT07321912Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RecruitingPhase 1/2
6 Months โ 25 Years ยท All sexes ยท Updated Jun 30, 2026 ยท NCT06625190XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Jun 18, 2026 ยท NCT06571734Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Recruiting
Ages 2 and older ยท All sexes ยท Updated Jun 4, 2026 ยท NCT07188532A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
Ages 16 and older ยท All sexes ยท Updated Jun 2, 2026 ยท NCT07197554Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
12 Months โ 30 Years ยท All sexes ยท Updated May 19, 2026 ยท NCT04901702B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 ยท All sexes ยท Updated May 19, 2026 ยท NCT04897321Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
RecruitingObservational study
Ages 4 and older ยท All sexes ยท Updated Apr 17, 2026 ยท NCT03442465Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RecruitingPhase 1
Ages 1 to 30 ยท All sexes ยท Updated Apr 15, 2026 ยท NCT04308330Single Arm Romiplostim to Prevent CIT
RecruitingEarly phase 1
Ages 1 and older ยท All sexes ยท Updated Mar 18, 2026 ยท NCT07048249Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RecruitingPhase 2
Ages 1 to 50 ยท All sexes ยท Updated Mar 13, 2026 ยท NCT01804634From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.